[ad_1]
The federal agency Anvisa stated that it does not see “any risk to the health of the population associated with the use of this vaccine” and authorized the vaccination of AstraZeneca not only in extreme conditions but also in general.
“The benefits outweigh the risks,” the agency said.
However, in the past, several countries, including Denmark, Norway, Bulgaria, and Thailand, have prevented vaccine prevention, following reports of blood clots in some people who have been vaccinated with AstraZeneca.
The European Medicines Agency (EMA), for its part, said on Friday that the warning about the possible side effects of the vaccine should be supplemented with a “severe allergic reaction.”
However, the World Health Organization (WHO) said there was no reason to stop taking AstraZeneca and described it as an “excellent vaccine.”
AstraZeneca said in its report that there was no evidence that people vaccinated with the vaccine had an increased risk of blood clots.
Anvisa has also approved the treatment of COVID-19 coronavirus infection with the antiviral drug remdesivir, although the WHO has found the effect on mortality in patients with coronavirus infection to be ‘low or non-existent’.
Brazil, severely affected by the coronavirus pandemic, with a population of 212 million, had difficulties obtaining vaccines. The country has also announced a purchase of 10 million doses of Sputnik V, a drug developed in Russia.
However, this vaccine has not yet been approved in Brazil. To date, only AstraZeneca and CoronaVac, a vaccine developed in China, have been used in the country.
Both vaccines are given in two doses.
In Brazil, about 9.3 million people have received the first dose of the vaccine so far. people; about 3.3 million population has already been vaccinated with a second dose.
More than 273 thousand people died in the country. people infected with coronavirus, according to statistics from the Ministry of Health. The country ranks second in the world after the United States in terms of COVID-19 victims.
[ad_2]
